To meet growing demands of advanced therapy manufacturing, production architectures must shift towards agile, efficient manufacturing systems. By integrating robotic gloveless isolator (RGI) technology into bioproduction, manufacturers can meet the needs of plasmid DNA, viral vector, and mRNA-based medicines while maintaining compliance with stringent regulatory standards.
Read the full article by Peter Boman (NorthX Biologics), and Zach Hartman (Cytiva), in Cell & Gene Therapy Insights here.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
The complex journey of bringing a biologic to market – part 6 As SOL-116 progresses toward Phase II trials, stability becomes a central focus in ensuring the product remains safe, ...
When we hosted the workshop “Growing Together: Navigating CDMO Partnerships Through Clinical Phases” at Nordic Life Science Days in Gothenburg, we hoped to start a dialogue about what truly makes ...
The complex journey of bringing a biologic to market – part 5 With GMP production of SOL-116 completed, the focus shifts to Fill & Finish—the step where drug substance becomes ...